Sight Diagnostics® Expands to Nordics and Baltics, Bringing AI-Powered, Fingerprick Blood Testing To Eight More Countries in Europe

Tel Aviv, Israel (November 4, 2021) - Sight Diagnostics, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, today announced its expansion to the Nordic and Baltic States in an effort to bring decentralized, fast, accurate, and convenient blood testing where it’s needed most. Through its distribution partner Carbon Health Labs, Sight will deploy its AI-powered CBC analyzer, Sight OLO®, in Norway, Sweden, Finland, Denmark, Iceland, Estonia, Lithuania, and Latvia. 

Given that the Nordics are sparsely populated, countries in the region started to invest in digital health tools even pre-pandemic, as delivering quality care in these remote settings remains challenging. CBC testing plays an essential role in healthcare providers’ ability to make critical decisions about a patient’s health. With OLO more than 33 million people in the Nordic and Baltic countries can now have access to convenient CBC testing in minutes.

OLO is a compact analyzer that attains the levels of accuracy expected from lab-based instruments optionally using fingerprick samples while avoiding much of the complexity, maintenance and operational overhead demanded by traditional systems. The innovative design enables the same healthcare worker to draw the blood, run the test, and obtain results within minutes, in contrast with the days that it typically takes to send blood tubes and obtain results from centralized labs. By implementing the Sight OLO in local health facilities, patients will have access to critical information about their health in minutes, dramatically expediting treatment decisions and improving patient experience.

“As a clinical consultant for over 25 years, I can see that OLO has the potential to save me hours of work. It’s now possible to shorten or eliminate treatment delays for a number of conditions, to improve the quality of care to a new level,” says Dr. Shwan Kizil, M.D., Ph.D., specialist in General Medicine and Pediatric Surgery previously at Akademiska Hospital, Uppsala.

The Nordic and Baltic states are the most recent regions to adopt OLO, following Sight’s expansion into the United Arab Emirates (UAE) in 2020 and Canada earlier in 2021. 

Along with its expanding global footprint, the company is also gaining momentum in the United States, where it was recently recognized as one of three semifinalist companies for the accredited American Association of Clinical Chemistry (AACC) 2021 Disruptive Technology Award. Additionally, Sight was named a finalist, among over 1,000 applicants, of the esteemed UCSF Digital Health Awards in the “New Health Application of AI” category. Both of these awards recognize Sight’s unique ability to provide lab-grade CBC results in minutes by leveraging artificial intelligence to digitize fingerprick blood samples at near-patient settings rapidly.

“Having access to fast, accurate and convenient testing is essential to improving health everywhere, and Sight’s technology is particularly suited for remote healthcare settings,” says Yossi Pollak, CEO and Co-Founder of Sight Diagnostics. “We’re thrilled to work with Carbon Health Labs to bring our clinically-validated CBC testing technology to the Nordics and Baltics to support their focus on digital health innovation.”

*Sight OLO is CE Marked according to the European IVD Directive at point of care settings. In the United States, Sight OLO is 510(k) cleared for use in moderate complexity laboratories.

About Sight Diagnostics 

Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and convenient diagnostic testing. Sight’s technology, developed over a decade of research, represents breakthrough innovations in artificial intelligence (AI) sample processing. Sight’s latest blood analyzer, OLO, performs a Complete Blood Count, the most commonly ordered blood test worldwide, in just minutes. OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a fingerprick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight’s first product, ParasightTM, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the US, UK, and Israel. Learn more at www.SightDX.com. 

About Carbon Health Labs 

Carbon Health Labs was founded in 2011 with the goal of putting the patient at the center of the care model. Carbon Health Labs distributes healthcare technology solutions from its in-house research and development team and also from other manufacturers with the aim to increase both patient safety and treatment quality. Carbon Group assists the healthcare sector in keeping up with development and transformation of the healthcare organisation. The products are tested, certified and quality approved according to current legislations. Learn more at https://www.carbonhealthlabs.com/.

Contact Information

Gabriela Lund

Media Contact

VSC for Sight Diagnostics

sight@vsc.co